ArticleScientific reports2025
AI-enhanced rapid diagnostic testing platform for mass opisthorchiasis screening.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cholangiocarcinoma (CCA) is a prevalent malignancy in countries along Mekong basin, closely linked to chronic infections caused by Opisthorchis viverrini (OV). Early detection of OV-infected individuals holds significant promise for screening at-risk populations in endemic regions. Recent advancements in immunochromatographic methods have led to the development of a rapid diagnostic test (RDT) based on urinary antigens. However, the current interpretation relies on visual assessment of T-band color intensity, which can be subjective and prone to variability. Furthermore, aggregating data at the regional/country level demands data digitization, a time and resource intense task that introduces further errors. To address this limitation, we introduce the OV-RDT platform, a cloud-based system incorporating artificial intelligence (AI) designed to standardize the reading and interpretation of OV-RDT results while facilitating mass screening campaigns for opisthorchiasis. This cross-platform solution, available on Android and iOS devices, consists of three key components: a mobile application, an intelligent dashboard, and a cloud server cluster. The server cluster has two main components the data processing server and the AI server. The AI server operates two AI-based models systematically developed and validated for image quality assessment and T-band grading of OV-RDT test kit images. The data processing server periodically retrieves and processes data from the cloud database, enabling comprehensive daily visualization through the intelligent dashboard. Validation through extensive field testing was conducted specifically in the northeastern region of Thailand, where opisthorchiasis prevalence is among the highest globally, demonstrating remarkable effectiveness by processing over 100,000 samples. While our platform shows excellent performance in this endemic region, external validation in other geographical areas would be necessary to establish broader generalizability. The EfficientNet-B5-based deep learning model used in the platform exhibited impressive performance in both image quality assessment (98% accuracy) and infection grading classification (95% accuracy in detecting OV infection status). The platform's user-friendly interface has achieved high satisfaction rates (4.41/5.00) among healthcare workers, while its intelligent dashboard offers real-time analytics and geospatial visualization capabilities. This integrated approach marks a significant advancement in mass screening for opisthorchiasis, potentially enhancing early detection rates and supporting more effective public health interventions in Southeast Asia and the Mekong Basin countries. This study addresses the critical need for mass screening in northeastern Thailand, where liver fluke infection rates are particularly severe; however, the platform's performance in other regions requires future validation studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.